Neonatal outcomes in pregnant women with immune thrombocytop
Thrombocytopenia is an autoimmune disorder characterized by reduced platelet counts. Neonatal thrombocytopenia incidence has been linked with immune thrombocytopenic purpura in mothers during pregnancy, possibly because antiplatelet antibodies can cross the placental barrier.

Investigators want to evaluate the overall prevalence of neonatal thrombocytopenia, its severity, and the incidence of hemorrhage in infants with thrombocytopenia born from mothers with immune thrombocytopenic purpura.

Adhering to PRISMA guidelines, researchers systematically scanned four academic databases including EMBASE, CENTRAL, Scopus, and MEDLINE to identify relevant literature. They performed a meta-analysis to summarize thrombocytopenia incidence rate and severity in newborn infants of mothers with immune thrombocytopenic purpura.

They identified 21 eligible studies involving 1951 mothers and 1844 neonates.

- Meta-analysis showed a high prevalence of neonatal thrombocytopenia. Within these, severe cases were the most prevalent, followed by moderate and mild cases.

- Hemorrhage was only reported in 4.1% of the observed neonatal thrombocytopenia cases.

To summarize, the review provides preliminary evidence that neonatal thrombocytopenia incidence is high in infants born to mothers with immune thrombocytopenic purpura. It further reports that the largest proportion of these cases are severe.

The Journal of Obstetrics & Gynecology Research